David B. Volkin BA, PhD

Dr. Volkin is the Ronald T. Borchardt Distinguished Professor of Pharmaceutical Chemistry, and co-founder of the Vaccine Analytics and Formulation Center (VAFC) at The University of Kansas. The VAFC collaborates extensively with partners (non-profits, small/large biopharma/vaccine companies, and academia) on analytical characterization and formulation development projects to facilitate novel candidates entering clinical trials with an emphasis on new candidates for use in the developing world. He has collaborated on the analytical and formulation development of ~100 biotherapeutic and vaccine candidates during ~10 years at KU including now marketed products (recombinant HA flu vaccine (FluBlok™) and an oncolytic herpes virus-based therapy, (T-VEC™) as well as late-stage clinical candidates (a live multivalent dengue virus vaccine candidate (TAK-003) and a recombinant non-replicating rotavirus vaccine, (NRRV).